for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Mustang Bio Inc

MBIO.O

Latest Trade

3.14USD

Change

0.01(+0.32%)

Volume

1,099,798

Today's Range

3.08

 - 

3.26

52 Week Range

1.78

 - 

4.85

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.13
Open
3.11
Volume
1,099,798
3M AVG Volume
27.01
Today's High
3.26
Today's Low
3.08
52 Week High
4.85
52 Week Low
1.78
Shares Out (MIL)
56.57
Market Cap (MIL)
177.08
Forward P/E
-2.87
Dividend (Yield %)
--

Latest Developments

More

Mustang Bio Announces Orphan Drug Designation for MB-207

Mustang Bio Reports Q2 Loss Per Share $0.32

Mustang Bio Announces Pricing Of Public Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Mustang Bio Inc

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on translating medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. The Company’s pipeline is focused in three areas: gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors. MB-107 is an Ex vivo Lentiviral Therapy for X-linked Severe Combined Immunodeficiency. Its MB-102 is a CD123 CAR T cell Program for acute myeloid leukemia (AML).

Industry

Biotechnology & Drugs

Contact Info

2 Gansevoort St Fl 9

NEW YORK, NY

10014-1667

United States

+1.781.6524507

http://www.mustangbio.com/

Executive Leadership

Michael S. Weiss

Executive Chairman of the Board

Manuel Litchman

President, Chief Executive Officer, Director

Brian Achenbach

Senior Vice President - Finance, Corporate Controller

Lindsay A. Rosenwald

Director

Adam J. Chill

Independent Director

Key Stats

1.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-1.240

2018

-1.140

2019

-1.290

2020(E)

-1.090
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
2.45
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
19.65
LT Debt To Equity (MRQ)
12.61
Return on Investment (TTM)
-62.77
Return on Equity (TTM)
-55.77

Latest News

Latest News

BRIEF-Mustang Bio Announces Pricing Of Public Offering Of Common Stock

* MUSTANG BIO ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Mustang Bio Announces Proposed Public Offering Of Common Stock

* MUSTANG BIO ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Mustang Bio Receives Advanced Therapy Medicinal Product Classification For Mb-107 Lentiviral Gene Therapy

* MUSTANG BIO RECEIVES ADVANCED THERAPY MEDICINAL PRODUCT CLASSIFICATION FROM EUROPEAN MEDICINES AGENCY FOR MB-107 LENTIVIRAL GENE THERAPY FOR X-LINKED SEVERE COMBINED IMMUNODEFICIENCY Source text for Eikon: Further company coverage:

BRIEF-Mustang Bio Announces First Subject Treated In Phase 1/2 Trial With The Optimized CD20-Targeted Car T Cell Therapy MB-106

* MUSTANG BIO ANNOUNCES FIRST SUBJECT TREATED IN PHASE 1/2 TRIAL WITH THE OPTIMIZED CD20-TARGETED CAR T CELL THERAPY MB-106 Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up